Navigation Links
Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
Date:4/29/2011

eatment.  

About COPDChronic obstructive pulmonary disease (COPD) is a preventable and treatable lung disease that is the fourth leading cause of death in the United States. Each year 12 million Americans are diagnosed with COPD and an additional 12 million Americans may have COPD but remain undiagnosed. Research shows that many do not get optimal treatment.

Bronchodilator medications are central to symptom management and are prescribed on an as-needed or regular basis to prevent or reduce symptoms. Long-acting inhaled bronchodilators have been shown to be most effective and convenient. Combining bronchodilators of different pharmacological classes, as recommended by The Global Initiative for Chronic Obstructive Lung Diseases (GOLD), has been shown to improve efficacy and may decrease the risk of side effects compared to increasing the dose of a single bronchodilator. As the course of COPD progresses, regular treatment with inhaled glucocorticosteroids may be added to bronchodilator treatment. Pearl is developing inhaled combination products designed to optimize the treatment of COPD.

About Pearl Therapeutics Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003 (GFF-MDI), an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010 (GMFF MDI), a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary poro
'/>"/>

SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
2. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
3. United Therapeutics Corporation Reports First Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
5. Prime Therapeutics President and CEO Eric Elliott Delivers Speech at University of Minnesota College of Pharmacy Dialogues in Managed Care Leadership 2011
6. Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
7. JumpStart Ventures Invests in Cleveland-based SPR Therapeutics
8. New Biopharmaceutical Company to Accelerate Delivery of Vaccines and Protein Therapeutics
9. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
10. Mersana Therapeutics Appoints Michael A. Metzger as EVP & COO
11. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
(Date:9/18/2014)... 18, 2014  A $3 million grant from The ... of Michigan to establish a national center of excellence ... for Aging Research at U-M will focus on exploiting ... the effects of aging and postpone diseases in animal ... can help develop medications that may help people live ...
(Date:9/18/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and Drug Administration (FDA) has removed the clinical ... in SWOG,s ongoing Phase 1b/2 clinical trial (S1313). ... drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination ... metastatic pancreatic adenocarcinoma.  The study will resume under ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... patients seeking care at larger urban hospitals are likely to ... at smaller or more rural facilities, new research suggests. ... emergency care varies dramatically across hospitals in the United States," ... Renee Hsia, an associate professor at the University of California, ...
(Date:9/18/2014)... Chest Physicians (CHEST) together with the Chinese Thoracic ... of CTS that CHEST World Congress 2016 will ... critical care, and sleep medicine from around the ... slated for spring 2016. , CHEST World ... hands-on simulation training, keynote addresses, presentations by leading ...
(Date:9/18/2014)... September 18, 2014 Qualis Health, one ... published a white paper, “Advancing Primary Care through ... Information Technology.” , Authors Jeff Hummel, MD, MPH ... guidance to organizations engaged in the work of becoming ... IT can bolster PCMH objectives, such as generating and ...
(Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
Breaking Medicine News(10 mins):Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2
... small number of teenagers, including non-smokers, are misusing nicotine patches ... could be setting themselves up for health trouble if they ... time or if they use the products to maintain their ... says the students may have lied on the survey. And ...
... to Russian universities has picked up after a six ... Medical Council Act in March 2002. ,This was evident ... universities jointly organized by the Russian Cultural Centre and ... to the organisers, at least 235 students had applied ...
... lower the risk of pre-eclampsia, doctors say. ,Their review ... women can reduce the risk of perinatal death and ... pre-eclampsia or who had chronic hypertension, diabetes or renal ... to 150 mg) //of aspirin were less likely to ...
... to be a better treatment than the antiplatelet drug ... to new research in this week’s issue of the ... black men and women who recently had strokes that ... to blockage of a blood vessel in the brain. ...
... kidney transplant patients reduce their risk of heart attacks, ... been shown to minimize cardiovascular disease in people with ... people with normal cholesterol levels who have other conditions ... Kidney transplant patients have a significantly //higher risk of ...
... who grow slowly in their first year of life ... true regardless of the socioeconomic status of the child's ... by hampered brain development. Biological processes linked to poor ... function with consequent lower //occupational status and income. ...
Cached Medicine News:Health News:Teens Misusing Nicotine-Replacement Products 2Health News:Admission to Russian varsities is looking up 2
... Counter allows the user to quickly and accurately ... for digital counting or manual counting. An optional ... increasing magnification to 3.0X. The adjustable focusing rod ... or lowered. The lens also rotates a full ...
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
... is a Accelerated Bacterial Enumeration System. Bacterial ... of colonies found by the volume dispensed ... A logarithmically decreasing volume of sample is ... Petri dish in an Archimedes spiral. The ...
... CEQ 8000 is a fully automated ... the capillary array with a patented linear ... sample, applies the voltage program, and analyzes ... review data quality and even customize automated ...
Medicine Products: